These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28698994)

  • 1. Prognostic importance of sodium level trajectory in acute heart failure.
    Matsue Y; Yoshioka K; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    Heart Vessels; 2017 Dec; 32(12):1498-1505. PubMed ID: 28698994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
    Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
    Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery from hyponatremia in acute phase is associated with better in-hospital mortality rate in acute heart failure syndrome.
    Yoshioka K; Matsue Y; Kagiyama N; Yoshida K; Kume T; Okura H; Suzuki M; Matsumura A; Yoshida K; Hashimoto Y
    J Cardiol; 2016 May; 67(5):406-11. PubMed ID: 26970933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    Int J Cardiol; 2016 Oct; 221():188-93. PubMed ID: 27404673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment.
    Matsumura K; Morishita S; Taniguchi N; Takehana K; Takahashi H; Otagaki M; Yoshioka K; Yamamoto Y; Takagi M; Shiojima I
    Heart Vessels; 2019 Apr; 34(4):607-615. PubMed ID: 30386917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.
    Shanmugam E; Doss CR; George M; Jena A; Rajaram M; Ramaraj B; Anjaneyan K; Kanagesh B
    Indian Heart J; 2016 Apr; 68 Suppl 1(Suppl 1):S15-21. PubMed ID: 27056648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload.
    Sato Y; Dohi K; Watanabe K; Tanimura M; Takeuchi T; Sugiura E; Sugimoto T; Kumagai N; Ogura T; Nakamori S; Fujimoto N; Yamada N; Ito M
    Int Heart J; 2016; 57(2):211-9. PubMed ID: 26973271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Discharge Hyponatremia in Heart Failure Patients With Normal Admission Sodium (from the ESCAPE Trial).
    Omar HR; Charnigo R; Guglin M
    Am J Cardiol; 2017 Aug; 120(4):607-615. PubMed ID: 28669488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of serum sodium in a population undergoing cardiac resynchronisation therapy.
    Guha K; Spießhöfer J; Hartley A; Pearse S; Xiu PY; Sharma R
    Indian Heart J; 2017; 69(5):613-618. PubMed ID: 29054185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
    Rossi J; Bayram M; Udelson JE; Lloyd-Jones D; Adams KF; Oconnor CM; Stough WG; Ouyang J; Shin DD; Orlandi C; Gheorghiade M
    Acute Card Care; 2007; 9(2):82-6. PubMed ID: 17573581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic benefit of acute heart failure associated with atherosclerosis: the importance of prehospital medication in patients with severely decompensated acute heart failure.
    Okazaki H; Shirakabe A; Hata N; Kobayashi N; Matsushita M; Shibata Y; Nishigoori S; Uchiyama S; Kiuchi K; Asai K; Shimizu W
    Heart Vessels; 2018 Dec; 33(12):1496-1504. PubMed ID: 29943232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure.
    Shirakabe A; Hata N; Yamamoto M; Kobayashi N; Shinada T; Tomita K; Tsurumi M; Matsushita M; Okazaki H; Yamamoto Y; Yokoyama S; Asai K; Shimizu W
    Circ J; 2014; 78(4):911-21. PubMed ID: 24553192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
    Wang C; Xiong B; Cai L
    BMC Cardiovasc Disord; 2017 Jun; 17(1):164. PubMed ID: 28633650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein level on admission and time to and cause of death in patients hospitalized for acute heart failure.
    Minami Y; Kajimoto K; Sato N; Hagiwara N; Takano T;
    Eur Heart J Qual Care Clin Outcomes; 2017 Apr; 3(2):148-156. PubMed ID: 28927169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Long-Term Mortality in Patients With Acute Heart Failure.
    Jin M; Wei S; Gao R; Wang K; Xu X; Yao W; Zhang H; Zhou Y; Xu D; Zhou F; Li X
    Int Heart J; 2017 May; 58(3):409-415. PubMed ID: 28496020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.